Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis

Regulation of bone mass through pineal-derived melatonin-MT2 receptor pathway

(2017) Kunal Sharan et al.   JOURNAL OF PINEAL RESEARCH

Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS

(2017) L. Zhou et al.   OSTEOPOROSIS INTERNATIONAL

Melatonin promotes osteoblast differentiation by regulating Osterix protein stability and expression

(2017) Younho Han et al.   Scientific Reports

Melatonin: Buffering the Immune System

(2013) Antonio Carrillo-Vico et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Methyprednisolone i.v. alters levels of CGRP and melatonin in cluster headache patients

(2013) L Neeb et al.   JOURNAL OF HEADACHE AND PAIN

Bone Turnover and Metabolism in Patients with Early Multiple Sclerosis and Prevalent Bone Mass Deficit: A Population-Based Case-Control Study

(2012) Stine Marit Moen et al.   PLoS One

Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis

(2011) Lena Melamud et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target

(2009) Kenneth L. Becker et al.   BRITISH JOURNAL OF PHARMACOLOGY

The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis

(2008) Zehra Akpınar et al.   PSYCHIATRY RESEARCH